BG Medicine, Inc.

BG Medicine, Inc. Appoints Eric Bouvier as Chief Executive Officer

BG Medicine, Inc. Appoints Eric Bouvier as Chief Executive Officer

January 9, 2012

WALTHAM, Mass., Jan. 9, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel, biomarker-based diagnostics, announced today that its Board of Directors has appointed Eric Bouvier, Ph.D., as the company's new President and Chief Executive Officer and a member of the Board of Directors, effective as of January 9, 2012.

Blend Therapeutics Founded by Leading Researchers in Chemistry and Nanomedicine to Develop a New Class of Integrative Combination Medicines

Blend Therapeutics Founded by Leading Researchers in Chemistry and Nanomedicine to Develop a New Class of Integrative Combination Medicines

January 6, 2012

WATERTOWN, Mass., Jan 06, 2012 (BUSINESS WIRE) -- Blend Therapeutics, a biotechnology company discovering and developing a new class of integrative combination medicines, announced the company's founding and strategic mission to develop innovative combination medicines with novel pharmacological profiles designed to target distinct disease pathways with optimal efficacy and safety.

Avedro, Inc.

Avedro Announces CE Approval for Lasik Xtra ™

Avedro Announces CE Approval for Lasik Xtra ™

January 4, 2012

Waltham, Massachusetts, USA, January 4, 2012 -- Avedro, Inc. announced today that the Company’s proprietary Lasik Xtra procedure has received CE Approval. Lasik Xtra is a two minute procedure used in conjunction with standard Lasik to restore the biomechanical integrity and strength to the cornea after a Lasik procedure. Lasik Xtra has been successfully used in thousands of Lasik surgeries outside the US.

Ensemble Therapeutics Corporation

Ensemble Therapeutics Advances Macrocycle IL-17 Antagonist Program: Reports First Known Small Molecule Inhibitors of Important Autoimmune Target

Ensemble Therapeutics Advances Macrocycle IL-17 Antagonist Program: Reports First Known Small Molecule Inhibitors of Important Autoimmune Target

January 5, 2012

CAMBRIDGE, MA – January 5, 2012 -- Ensemble Therapeutics, a biotechnology company developing EnsemblinsTM, a novel class of small molecule therapeutics with the power of biologics, announced today that the company has identified a series of unique small molecule antagonists of Interleukin-17, a pro-inflammatory cytokine implicated in multiple inflammatory and autoimmune diseases such as psoriasis, rheumatoid arthritis, Crohn’s and intestinal bowel disease.

Ensemble Therapeutics Corporation

Ensemble Therapeutics Extends Macrocycle Drug Discovery Alliance with Bristol-Myers Squibb

Ensemble Therapeutics Extends Macrocycle Drug Discovery Alliance with Bristol-Myers Squibb

January 5, 2012

CAMBRIDGE, MA – January 5, 2012 -- Ensemble Therapeutics, a biotechnology company developing EnsemblinsTM, a novel class of small molecule therapeutics with the power of biologics, announced today the extension of its strategic alliance with Bristol-Myers Squibb (NYSE: BMS), building on a collaboration initiated in April 2009.

CIA's In-Q-Tel makes strategic investment in Quanterix

CIA's In-Q-Tel makes strategic investment in Quanterix

January 5, 2012

Quanterix Corp. has taken a strategic investment for an undisclosed amount from In-Q-Tel, the investment arm of the CIA, to help expand development of its technology to detect pathogens.

Please click on Mass High Tech logo to view full article

Drawing blood with a tap, not a sting - Cambridge firm’s device uses tiny needles, vacuum for painless diagnostic tests

Drawing blood with a tap, not a sting - Cambridge firm’s device uses tiny needles, vacuum for painless diagnostic tests

January 2, 2012

Pop culture has developed an appetite for blood, but the average American still cowers at the sight of a needle.

What if giving blood was as easy and painless as a tap on the arm? Engineers at Seventh Sense Biosystems in Cambridge have been working for two years to make that so. And they are getting close.
 

Please click on Boston.com logo to view full article.

 

Acceleron Pharma, Inc.

Acceleron Secures $30M Private Financing

Acceleron Secures $30M Private Financing

December 23, 2011

CAMBRIDGE, Mass. – December 23, 2011 –  Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today announced it raised a $30M private financing.  Celgene, one of Acceleron’s strategic partners, and all other existing investors participated in this financing.  The proceeds will be used to expand and advance Acceleron’s clinical stage pipeline and to continue to support its highly productive research engine.
 

BG Medicine, Inc.

BG Medicine, Inc. Files 510(k) for AMIPredict

BG Medicine, Inc. Files 510(k) for AMIPredict

December 28, 2011

WALTHAM, Mass., Dec. 28, 2011 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel, biomarker-based diagnostics, announced today that it has filed a 510(k) Premarket Notification with the U.S. Food and Drug Administration (FDA) for regulatory clearance of the company's second cardiovascular diagnostic test, AMIPredict. The filing was made following the successful completion of a validation study using data from the company's BioImage Study, which involved approximately 6,600 individuals.

Quanterix Corporation

Quanterix Develops Microfluidic Consumable That Will Enable Next Generation Molecular Diagnostic Systems based on Single Molecule Array Technology

Quanterix Develops Microfluidic Consumable That Will Enable Next Generation Molecular Diagnostic Systems based on Single Molecule Array Technology

December 22, 2011

CAMBRIDGE, Mass., Dec. 22, 2011 /PRNewswire/ -- Quanterix Corporation, a company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array (SiMoA™) technology, has reported a method for detecting individual proteins within microfabricated polymer arrays produced by Sony DADC.  Quanterix recently entered into a collaboration with Sony DADC for the development and manufacture of "smart consumables" based on an optical disc format.  This method was published online in Lab on a Chip.